Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with clinical acronyms, collaboration milestones, and manufacturing risk factors can feel overwhelming. Legend Biotech’s disclosures often exceed 200 pages and weave together laboratory data, cell-therapy manufacturing updates, and joint-development revenue—all details investors must grasp before making a decision.
Stock Titan turns that complexity into clarity. Our AI-powered summaries dissect each Legend Biotech annual report 10-K simplified, highlight pivotal trial results within every Legend Biotech quarterly earnings report 10-Q filing, and surface insider confidence with Legend Biotech Form 4 insider transactions real-time. Rather skim key facts? The platform flags material events in the latest Legend Biotech 8-K material events explained and answers the common request for “Legend Biotech SEC filings explained simply.”
Explore exactly where the value lies:
- Track Legend Biotech insider trading Form 4 transactions to spot executive sentiment.
- Dive into Legend Biotech earnings report filing analysis to compare R&D spend against collaboration income.
- Review the Legend Biotech proxy statement executive compensation to understand how clinical milestones drive pay packages.
With real-time EDGAR updates, expert commentary, and AI models dedicated to understanding Legend Biotech SEC documents with AI, you’ll monitor manufacturing scale-up risks, patent timelines, and cash runway without combing through footnotes. Investors, analysts, and researchers rely on our comprehensive coverage of ALL filing types—10-K, 10-Q, 8-K, S-3, and, of course, the Legend Biotech executive stock transactions Form 4—to stay ahead of critical developments.
Legend Biotech (LEGN) reported sharply higher revenue and narrower losses for Q3 2025. Total revenue reached $272.3 million, driven by collaboration revenue of $261.8 million tied to CARVYKTI sales. Operating loss improved to $43.5 million from $70.4 million, and net loss narrowed to $39.7 million from $125.3 million.
For the nine months ended September 30, revenue rose to $722.5 million from $440.7 million as CARVYKTI commercialization scaled. Year‑to‑date results were weighed by $162.4 million of other expense primarily from unrealized foreign exchange losses on USD/EUR balances. Adjusted net loss for the nine months was $35.7 million.
Cash and cash equivalents were $278.9 million and time deposits were $713.7 million (about $1.0 billion combined) as of September 30, 2025. The company noted CARVYKTI net trade sales of approximately $524 million, over 9,000 patients treated to date, and the start of commercial production at its Tech Lane site in Belgium. Collaboration interest‑bearing advanced funding totaled $314.8 million, with $142.9 million estimated to be recouped by Janssen within twelve months.
Legend Biotech (LEGN) announced upcoming clinical data visibility at ASH 2025. The company will deliver 10 presentations at the 67th American Society of Hematology Annual Meeting, held December 6–9, 2025 in Orlando, FL. The slate includes two oral presentations and seven posters on CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma, plus one oral presentation on Lucar-G39D, an investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy in relapsed or refractory B-cell non-Hodgkin lymphoma.
The report is incorporated by reference into Legend Biotech’s Form F-3 and Form S-8 registration statements.
Legend Biotech (LEGN) announced U.S. FDA approval of a CARVYKTI label update to include overall survival (OS) results from the Phase 3 CARTITUDE-4 study. The update states CARVYKTI showed a statistically significant OS improvement versus standard of care in relapsed/refractory multiple myeloma after one to three prior lines of therapy. At a median follow-up of 33.6 months, neither treatment arm reached median OS, indicating durable survival has not yet been fully characterized.
The label also adds immune effector cell‑associated enterocolitis (IEC‑EC) to the Boxed Warnings and Warnings and Precautions, noting cases with severe or prolonged diarrhea, abdominal pain, weight loss, and rare fatalities from perforation or sepsis. Additionally, John Cunningham (JC) virus reactivation leading to progressive multifocal leukoencephalopathy (PML) was added to Warnings and Precautions (Infections) and Postmarketing Experience, including fatal cases. Physicians are advised to follow institutional guidelines for IEC‑EC management and conduct appropriate diagnostic evaluations for neurological events.
Legend Biotech (LEGN) reported preliminary CARVYKTI sales of approximately $524 million in net trade sales for the quarter ended September 30, 2025. The figure was provided by collaboration partner Janssen under their existing agreement.
Legend Biotech noted it has not independently verified this sales number. The final determination of revenue and gross profit for this period will be made upon completion of its financial statements, and the company’s independent auditors have not audited or reviewed the data. The filing also includes forward‑looking statements language regarding expectations for CARVYKTI sales and profitability.
Form 144 notice for Legend Biotech Corp (LEGN) reports a proposed sale of 1,000 American Depositary Shares through Fidelity Brokerage Services with an aggregate market value of $33,285 and an approximate sale date of 09/26/2025 on NASDAQ. The shares were acquired on 06/20/2022 as restricted stock vesting from the issuer and were paid as compensation. The filing lists 367,298,315 shares outstanding for the class and discloses a prior sale by Patrick Casey of 1,000 ADS on 06/26/2025 for $33,234. The filer signs the required representation that they are unaware of material nonpublic information.
Legend Biotech (LEGN) Form 144 disclosure: The filing notifies a proposed sale of 1,370 American Depositary Shares (ADS) valued at $45,210 to be sold via Fidelity Brokerage Services on NASDAQ on 09/24/2025. The shares were acquired 09/20/2025 through restricted stock vesting and were received as compensation. The filing also reports four prior ADS sales by the same person (Ying Huang) during the past three months totaling 40,577 ADS with gross proceeds of $1,566,086.36.
Legend Biotech Corp (LEGN) reported a Form 144 notice showing proposed sale of 1,357 American Depositary Shares through Fidelity Brokerage, listed on NASDAQ, with an aggregate market value of $46,111.81 and approximately 367,298,315 shares outstanding. The shares were acquired on 09/19/2025 through restricted stock vesting as compensation and the planned sale date is 09/23/2025. The filer also reported three prior ADS sales in June–July 2025 totaling 38,220 shares for gross proceeds of $1,505,975.55. The filing represents a routine insider sale report under Rule 144.
Legend Biotech Corp (LEGN) Form 144 summary: An insider plans to sell 474 American Depositary Shares on 09/23/2025 through Fidelity Brokerage Services. The shares were acquired on 09/19/2025 by Restricted Stock Vesting and were paid as compensation. The aggregate market value of the proposed sale is listed as $16,106.85, with the issuer's outstanding shares shown as 367,298,315. The filing also discloses a prior sale by the same person: 642 ADS sold on 07/23/2025 for $28,890.00. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Form 144 notice for Legend Biotech Corp (LEGN) reports a proposed sale of 307 American Depositary Shares (ADSs) with an aggregate market value of $10,438 and approximately 367,298,315 ADSs outstanding. The securities were acquired on 09/20/2025 through restricted stock vesting from the issuer and the stated nature of payment is compensation. The approximate date of sale listed is 09/23/2025. The filer also disclosed a prior sale on 06/24/2025 of 307 ADSs by Corazon D. Sanders for gross proceeds of $10,551.59. Several standard filing fields (issuer name, filer CIK/CCC, and contact details) appear blank in the provided content.
FAQ
What is the current stock price of Legend Biotech (LEGN)?
What is the market cap of Legend Biotech (LEGN)?
